# US 2015/0104450 A1 · CTLA-4 Variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104450 A1
- Document ID: US20150104450A1
- Status: Published application
- Kind: A1
- Application number: 14/399,685
- Filed: 2013-03-11
- Published: 2015-04-16
- Earliest claimed: 2012-05-11
- Assignees: MedImmune, LLC
- Applicants: MedImmune, LLC; MedImmune Limited
- Inventors: Ralph Minter; Julie Douthwaite; Jacques Moisan; Michael Bowen; Steven Rust; Cyril Privezentzev
- Web page: https://patentgrep.com/patent/US20150104450A1

## CPC

- C07K 14/70521: {CD28, CD152}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

## Claims

### Claim 1

An isolated CTLA-4 polypeptide having greater affinity for binding human CD80, greater potency and/or greater stability compared with wild type CTLA-4 SEQ ID NO: 35, the polypeptide comprising an amino acid sequence that is a variant of SEQ ID NO: 35, wherein the variant comprises five or more of the following amino acid mutations in SEQ ID NO: 35:
R, S, V or T at I16;
T at A24;
N or P at S25;
S at G27;
I at V 32;
G at D41;
G at S42;
E at V44;
K at M54;
S or G at N56;
A, G, S or P at L58;
S or A at T59;
T at F 60;
Q or P at L61;
G at D 62;
Y at D63;
P at S 64;
N, D, V or T at I65;
A, T, M or H at S70;
R at Q80;
Q, S, V, R, K or L at M85;
S at T87;
Q, H, T, E or M at K93;
R, Q or E at L104;
V at I106;
D or S at N108;
V or F at I115;
S at C120;
deletion at T51.

### Claim 2 (depends on 1)

A CTLA-4 polypeptide according to claim 1, wherein the polypeptide comprises an amino acid sequence at least 70% identical to SEQ ID NO: 35.

### Claim 3 (depends on 1, 2)

A CTLA-4 polypeptide according to claim 1 or claim 2, comprising five or more of the following amino acid mutations:
R, S or V at I16;
T at A24;
N at S25;
S at G27;
K at M54;
S at N56;
A or G at L58;
S at T59;
T at F60;
Q at L61;
Y at D63;
P at S64;
N or D at I65;
A at S70;
R at Q80;
Q or S at M85;
Q or H at K93;
S at C120.

### Claim 4 (depends on 1, 2)

A CTLA-4 polypeptide according to claim 1 or claim 2, comprising substitution S25N or S25P.

### Claim 5 (depends on 1, 2, 3)

A CTLA-4 polypeptide according to any of claims 1 to 3, comprising substitution S25N, K93Q or K93H.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A CTLA-4 polypeptide according to any of claims 1 to 5, comprising an amino acid sequence at least 70%, 80%, 90%, 95%, 98% or 99% identical with any of SEQ ID NOS: 36-55, or an amino acid sequence at least 70%, 80%, 90%, 95%, 98% or 99% identical with the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A CTLA-4 polypeptide according to any of claims 1 to 6, comprising an amino acid motif SEQ ID NO: 69 at residues 59-65, the residue numbering being with reference to SEQ ID NO: 35.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A CTLA-4 polypeptide according to any of claims 1 to 6, comprising a combination of mutations selected from:
the 1315 mutations i.e. S at I16; N at S25; G at L58; A at S70; R at Q80; S at M85; and Q at K93;
the 1322 mutations i.e. N at S25; S at G27; K at M54; S at N56; S at T59; T at F 60; Q at L61; Y at D63; P at S64; N at I65; and Q at K93;
the 1321 mutations i.e. S at I16; N at S25; K at M54; G at L58; A at S70; R at Q80; S at M85; and Q at K93;
the 1115 mutations i.e. V at I16; N at S25; G at L58; A at S70; Q at M85; and Q at K93;
the 1299 mutations i.e. R at I16; T at A24; N at S25; S at G27; A at L58; A at S70; Q at M85; and Q at K93; and
the 1227 mutations i.e. S at I16; N at S25; S at G27; A at L58; A at S70; Q at M85; and H at K93.

### Claim 9

A CTLA-4 polypeptide according to any of the preceding claims, comprising an amino acid sequence selected from SEQ ID NOS: 36-55 or comprising the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948, or comprising a variant of any of those sequences with up to ten amino acid mutations.

### Claim 10

A CTLA-4 polypeptide according to any of the preceding claims, comprising an amino acid sequence selected from SEQ ID NOS: 36-55 or comprising the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948, or comprising a variant of any of those sequences with up to five amino acid mutations.

### Claim 11 (depends on 10)

A CTLA-4 polypeptide according to claim 10, comprising an amino acid sequence selected from SEQ ID NOS: 36-55 or comprising the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948, or comprising a variant of any of those sequences with up to three amino acid mutations.

### Claim 12 (depends on 1, 2)

A CTLA-4 polypeptide according to claim 1 or claim 2, comprising an amino acid sequence selected from SEQ ID NOS: 36-55 or comprising the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948.

### Claim 13 (depends on 12)

A CTLA-4 polypeptide according to claim 12, comprising an amino acid sequence selected from SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 47 or the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948.

### Claim 14

An isolated CTLA-4 polypeptide having greater affinity for binding human CD80, greater potency and/or greater stability compared with wild type CTLA-4 SEQ ID NO: 35, wherein the polypeptide comprises:
(i) amino acid sequence SEQ ID NO: 68, SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 or SEQ ID NO: 47;
(ii) an amino acid sequence that is a variant of (i) containing up to ten amino acid mutations, wherein residue 25 is not mutated and is N;
(iii) an amino acid sequence that is a variant of (i) comprising one or more amino acid mutations, wherein residue 25 is not mutated and is N, the variant having at least 70% sequence identity to (i); or
(iv) a CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948.

### Claim 15 (depends on 14)

A CTLA-4 polypeptide according to claim 14, comprising SEQ ID NO: 68, SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 or SEQ ID NO: 47, or a variant of any of those sequences with up to five amino acid mutations.

### Claim 16 (depends on 15)

A CTLA-4 polypeptide according to claim 15, comprising SEQ ID NO: 68, SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 or SEQ ID NO: 47, or a variant of any of those sequences with up to three amino acid mutations.

### Claim 17 (depends on 14)

A CTLA-4 polypeptide according to claim 14, wherein the polypeptide comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 68, SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 or SEQ ID NO: 47.

### Claim 18 (depends on 17)

A CTLA-4 polypeptide according to claim 17, wherein the polypeptide comprises an amino acid sequence having at least 90%, 95%, 98% or 99% sequence identity to SEQ ID NO: 68, SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 or SEQ ID NO: 47.

### Claim 19

A CTLA-4 polypeptide according to any of the preceding claims, having an affinity of 50 nM or less for binding human CD80, wherein affinity is KD as determined by surface plasmon resonance.

### Claim 20 (depends on 19)

A CTLA-4 polypeptide according to claim 19, having an affinity of 20 nM or less for binding human CD80, wherein the affinity is KD as determined by surface plasmon resonance.

### Claim 21

A CTLA-4 polypeptide according to any of the preceding claims, wherein the polypeptide has greater affinity than wild type CTLA-4 (SEQ ID NO: 35) for binding human CD86.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

A CTLA-4 polypeptide according to any of claims 14 to 21, comprising:
S at residue 16; N at residue 25; G at residue 58; A at residue 70; R at residue 80; S at residue 85; and Q at residue 93;
N at residue 25; S at residue 27; K at residue 54; S at residue 56; S at residue 59; T at residue 60; Q at residue 61; Y at residue 63; P at residue 64; N at residue 65; and Q at residue 93;
S at residue 16; N at residue 25; K at residue 54; G at residue 58; A at residue 70; R at residue 80; S at residue 85; and Q at residue 93;
V at residue 16; N at residue 25; G at residue 58; A at residue 70; Q at residue 85; and Q at residue 93;
R at residue 16; T at residue 24; N at residue 25; S at residue 27; A at residue 58; A at residue 70; Q at residue 85; and Q at residue 93; or
S at residue 16; N at residue 25; S at residue 27; A at residue 58; A at residue 70; Q at residue 85; and H at residue 93.

### Claim 23 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22)

A CTLA-4 polypeptide according to any of claims 14 to 22, comprising amino acid sequence SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 or SEQ ID NO: 47, with up to three amino acid mutations.

### Claim 24 (depends on 14, 15, 16, 17, 18)

A CTLA-4 polypeptide according to any of claims 14 to 18, comprising: R, I, S or V at position 16; T or A at position 24; S or G at position 27; M or K at position 54; N or S at position 56; A, L or G at position 58; T or S at position 59; F or T at position 60; L or Q at position 61; D or Y at position 63; S or P at position 64; I, N or D at position 65; A or S at position 70; Q or R at position 80; Q, M or S at position 85; Q or H at position 93; and C or S at position 120.

### Claim 25 (depends on 14, 15, 16, 17, 18)

A CTLA-4 polypeptide according to any of claims 14 to 18, wherein the amino acid mutations are selected from the following: substitution T at residue 16; substitution I at residue 32; substitution G at residue 41; substitution G at residue 42; substitution E at residue 44; substitution G at residue 56; substitution S or P at residue 58; substitution A at residue 59; substitution P at residue 61; substitution G at residue 62; substitution V or T at residue 65; substitution T, M or H at residue 70; substitution V, R, K or L at residue 85; substitution S at residue 87; substitution T, E or M at residue 93; substitution R, Q or E at residue 104; substitution V at residue 106; substitution D or S at residue 108; substitution V or F at residue 115; substitution S at residue 120; deletion at residue 51.

### Claim 26 (depends on 14)

A CTLA-4 polypeptide according to claim 14, comprising amino acid sequence SEQ ID NO: 68, SEQ ID NO: 43, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 or SEQ ID NO: 47 or comprising a CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948.

### Claim 27

An isolated CTLA-4 polypeptide which has at least 10-fold greater affinity for binding CD80 than for binding CD86.

### Claim 28 (depends on 27)

A CTLA-4 polypeptide according to claim 27, which has at least 50-fold greater affinity for binding CD80 than for binding CD86.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A CTLA-4 polypeptide according to claim 27 or claim 28, wherein the polypeptide is as defined in any of claims 1 to 26.

### Claim 30

A CTLA-4 polypeptide according to any of the preceding claims, conjugated to an IgG Fc amino acid sequence.

### Claim 31 (depends on 30)

A CTLA-4 polypeptide according to claim 30, wherein the IgG Fc is a human IgG1 Fc modified to reduce Fc effector function, and comprises a native human IgG1 Fc hinge region.

### Claim 32 (depends on 30, 31)

A CTLA-4 polypeptide according to claim 30 or claim 31, wherein the IgG Fc amino acid sequence comprises a human IgG1 Fc region in which one or both of the following groups of residues are substituted as follows:
F at residue 20; E at residue 21; S at residue 117; and
Y at residue 38, T at residue 40, E at residue 42,
the residue numbering being defined with reference to SEQ ID NO: 56.

### Claim 33 (depends on 30, 31, 32)

A CTLA-4 polypeptide according to any of claims 30 to 32, wherein the IgG Fc amino acid sequence comprises SEQ ID NO: 59.

### Claim 34

An isolated CTLA-4 polypeptide comprising the 1299 CTLA-4-Ig amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948.

### Claim 35

A CTLA-4 polypeptide according to any of the preceding claims, wherein the polypeptide is in a multimer.

### Claim 36 (depends on 35)

A CTLA-4 polypeptide according to claim 35, wherein the CTLA-4 polypeptide is in a dimer.

### Claim 37 (depends on 35)

A CTLA-4 polypeptide according to claim 35, wherein the CTLA-4 polypeptide is in a tetramer.

### Claim 38 (depends on 37)

A CTLA-4 polypeptide according to claim 37, wherein the tetramer comprises two pairs of CTLA-4 polypeptides, each pair comprising a CTLA-4 polypeptide fused to an antibody light chain constant region and a CTLA-4 polypeptide fused to an antibody heavy chain constant region.

### Claim 39

A host cell containing nucleic acid, wherein the nucleic acid comprises the 1299 CTLA-4-Ig nucleic acid sequence deposited under NCIMB accession no. 41948.

### Claim 40

A composition comprising:
a CTLA-4 polypeptide according to any of the preceding claims; and
one or more pharmaceutical excipients.

### Claim 41

A composition comprising:
a CTLA-4 polypeptide comprising amino acid sequence SEQ ID NO: 68, SEQ ID NO: 43, SEQ ID NO: 47, SEQ ID NO: 38, SEQ ID NO: 36, SEQ ID NO: 42 SEQ ID NO: 47 or the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948, conjugated to an IgG Fc amino acid sequence; and
one or more pharmaceutical excipients.

### Claim 42 (depends on 40, 41)

A composition according to claim 40 or claim 41, wherein the CTLA-4 polypeptide is conjugated to an IgG Fc amino acid sequence comprising SEQ ID NO: 59.

### Claim 43 (depends on 42)

A composition according to claim 42, wherein the CTLA-4 polypeptide conjugated to an IgG Fc comprises amino acid sequence SEQ ID NO: 13, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15 or SEQ ID NO: 16.

### Claim 44

A composition comprising the 1299 CTLA-4-Ig polypeptide encoded by nucleic acid deposited under NCIMB accession no. 41948 and one or more pharmaceutical excipients.

### Claim 45 (depends on 40, 41, 42, 43, 44)

A composition according to any of claims 40 to 44, comprising the CTLA-4 polypeptide at a concentration of at least 70 mg/ml.

### Claim 46 (depends on 45)

A composition according to claim 45, comprising the CTLA-4 polypeptide at a concentration of at least 100 mg/ml.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46)

A CTLA-4 polypeptide according to any of claims 1 to 38, or a composition according to any of claims 40 to 46, for use in a method of treatment of a patient by subcutaneous or intravenous administration.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46)

A CTLA-4 polypeptide according to any of claims 1 to 38, or a composition according to any of claims 40 to 46, for use in a method of treatment of rheumatoid arthritis, multiple sclerosis, asthma, Crohn's disease, ulcerative colitis, systemic lupus erythematosus or transplant rejection.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46)

A CTLA-4 polypeptide according to any of claims 1 to 38, or a composition according to any of claims 40 to 46, for use in a method of treatment comprising administering said CTLA-4 polypeptide or said composition to a patient at 28 day intervals.

### Claim 50

A method of producing a further CTLA-4 polypeptide by mutation of a CTLA-4 polypeptide amino acid sequence selected from SEQ ID NOS 36-55 or the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948, the method comprising:
providing a CTLA-4 polypeptide comprising or consisting of amino acid sequence SEQ ID NOS 36-55 or the CTLA-4 amino acid sequence encoded by nucleic acid deposited under NCIMB accession no. 41948;
introducing one or more mutations in the amino acid sequence to provide a further CTLA-4 polypeptide;
testing stability, affinity and/or potency of the further CTLA-4 polypeptide; and
formulating the further CTLA-4 polypeptide into a composition comprising one or more pharmaceutical excipients.

### Claim 51 (depends on 50)

A method according to claim 50, wherein the further CTLA-4 polypeptide is conjugated to an Fc region.
